Skip to main content
    R

    Rhythm Pharmaceuticals Inc (RYTM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $107.48
    -7.54 (-6.56%)

    Market Cap: $7.97B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Rhythm Pharmaceuticals Inc (RYTM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Rhythm Pharmaceuticals reported revenue of $189.76M for the fiscal year ended Dec 31, 2025, up 45.8% from the year before. That year, net income was -$196.54M with a net margin of -103.6%, operating cash flow was -$115.67M and free cash flow was -$116.63M. The quarter ended Sep 30, 2026 had revenue of $92.13M and net income of -$41.37M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$189.76M+45.8%89.7%-101.2%-103.6%
    Dec 2024$130.13M+68.1%89.7%-204.0%-200.3%
    Dec 2023$77.43M+227.6%88.0%-238.1%-238.5%
    Dec 2022$23.64M+649.5%91.0%-757.9%-766.2%
    Dec 2021$3.15MN/A81.0%-5391.9%-2207.1%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$189.76M$130.13M$77.43M$23.64M$3.15M$0$0$0$0$0
    Cost of revenue$19.49M$13.37M$9.30M$2.13M$599.00K$0$0$0$0$0
    Gross profit$170.26M$116.76M$68.13M$21.50M$2.56M$0$0$0$0$0
    Research and development$167.34M$237.96M$134.95M$108.63M$104.13M$90.45M$109.45M$50.34M$22.89M$19.59M
    Operating income-$192.02M-$265.50M-$184.36M-$179.16M-$170.06M-$136.57M-$146.00M-$78.42M-$32.41M-$25.91M
    Net income-$196.54M-$260.60M-$184.68M-$181.12M-$69.61M-$134.00M-$140.73M-$74.06M-$33.71M-$25.87M
    EBITDAN/A-$260.97MN/AN/A-$68.90M-$135.88M-$139.90M-$77.97MN/A-$25.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$92.13M$71.25M$60.11M$57.25M$51.30M$48.50M$32.70M$41.83M$33.25M$29.08M$25.97M$24.23M
    Gross profit$79.96M$62.32M$52.95M$52.45M$45.80M$42.96M$29.06M$38.04M$29.42M$26.13M$23.16M$21.00M
    Operating income-$39.27M-$48.55M-$52.36M-$47.06M-$52.65M-$45.30M-$47.00M-$41.25M-$43.88M-$40.48M-$139.89M-$41.27M
    Net income-$41.37M-$49.30M-$55.64M-$47.51M-$52.90M-$46.63M-$49.50M-$43.33M-$43.64M-$32.26M-$141.37M-$41.63M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $108.18M exceeded cash and equivalents by $53.88M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$480.20M$392.27M$332.75M$382.48M$329.52M$187.07M$308.52M$260.21M$151.74M$12.34M
    Current assets$466.92M$374.20M$308.27M$354.24M$308.39M$181.67M$302.40M$258.69M$150.67M$11.18M
    Cash and equivalents$54.30M$89.14M$60.08M$127.68M$59.25M$100.85M$62.29M$49.54M$34.24M$6.54M
    Total liabilities$210.17M$227.72M$162.99M$118.22M$45.37M$20.55M$27.50M$13.95M$6.95M$5.04M
    Short-term debt$7.30M$1.54M$0$684.00K$606.00K$535.00K$472.00KN/AN/AN/A
    Long-term debt$100.89M$108.27M$106.14M$1.34MN/AN/AN/AN/A$0N/A
    Shareholder equity$139.07M$21.73M$169.76M$264.26M$284.15M$166.53M$281.02M$246.26M$144.79M-$32.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$443.13M$437.27M$442.32M$481.19M$506.87M$372.73M$386.69M$392.27M$363.57M$381.85M$258.65M$332.75M
    Total liabilities$241.59M$219.97M$204.70M$342.13M$211.19M$239.15M$223.60M$227.72M$210.88M$202.35M$197.07M$162.99M
    Cash and equivalents$39.98M$65.61M$62.14M$54.30M$52.08M$135.59M$106.09M$89.14M$47.52M$161.67M$53.43M$60.08M
    Shareholder equity$87.97M$102.98M$122.91M$139.07M$148.82M-$11.91M$18.95M$164.55M$11.21M$39.34M$61.58M$169.76M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$115.67M-$113.88M-$136.16M-$173.43M-$146.00M-$121.98M-$122.75M-$62.06M-$29.46M-$23.22M
    Capital expenditures$953.00K$0$47.00K$281.00K$434.00K$214.00K$3.38M$722.00K$133.00K$1.06M
    Free cash flow-$116.63M-$113.88M-$136.20M-$173.71M-$146.44M-$122.19M-$126.14M-$62.78M-$29.59M-$24.28M
    Dividends paid$5.38M$3.97MN/AN/AN/AN/AN/AN/A$0N/A
    Investing cash flow-$137.15M-$48.17M-$5.67M$28.03M-$62.16M$158.53M-$27.97M-$87.15M-$110.04M-$5.11M
    Financing cash flow$217.96M$191.24M$74.37M$213.83M$166.48M$2.01M$163.47M$164.69M$167.20M$0
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.06M-$9.15M-$44.19M-$25.39M-$26.62M-$23.31M-$40.35M-$18.84M-$25.21M-$29.08M-$40.74M-$29.38M
    Capital expendituresN/AN/A$0$953.00K$0$0$0$0$40.00M$0$40.00M$1.00K
    Free cash flowN/AN/A-$44.19M-$26.34M-$26.62M-$23.31M-$40.35M-$18.84M-$65.22M-$29.08M-$80.74M-$29.38M
    Last 12 quarters

    Frequently Asked Questions About RYTM

    What is Rhythm Pharmaceuticals' annual revenue?

    Rhythm Pharmaceuticals reported revenue of $189.76M for the fiscal year ended Dec 31, 2025.

    How fast is Rhythm Pharmaceuticals' revenue growing?

    Revenue was up 45.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 100.2%.

    Is Rhythm Pharmaceuticals profitable?

    No. Rhythm Pharmaceuticals reported net income of -$196.54M for the fiscal year ended Dec 31, 2025, with a net margin of -103.6%.

    How much free cash flow does RYTM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$115.67M minus capital expenditures of $953.00K produced free cash flow of -$116.63M.

    How much debt does Rhythm Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $100.89M, short-term debt of $7.30M and cash and equivalents of $54.30M.